Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Cardiology

Journal Scan / Research · April 22, 2024

Semaglutide vs Placebo in Patients With Obesity-Related HFpEF

The Lancet


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet
Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials
Lancet 2024 Apr 04;[EPub Ahead of Print], J Butler, SJ Shah, MC Petrie, BA Borlaug, SZ Abildstrøm, MJ Davies, GK Hovingh, DW Kitzman, DV Møller, S Verma, MN Einfeldt, ML Lindegaard, S Rasmussen, W Abhayaratna, FZ Ahmed, T Ben-Gal, V Chopra, JA Ezekowitz, M Fu, H Ito, M Lelonek, V Melenovský, B Merkely, J Núñez, E Perna, M Schou, M Senni, K Sharma, P van der Meer, D Von Lewinski, D Wolf, MN Kosiborod

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading